The Broad Institute of MIT and Harvard has extended a collaborative deal with IBM Watson Health. The three-year agreement follows the previous five-year deal signed in 2016 and will involve using AI to analyse and examine genomics data to better establish the natural possibility people have for a certain disease. “While we are excited about this new partnership, it is important that we understand how our work can be used by other researchers around the world,” said David Sinclair, director of the Broad Institute. Ultimately the initiative intends to make knowledge gained, along with accompanying tools, available to researchers.
The Broad Institute of MIT and Harvard has extended a collaborative deal with IBM Watson Health. The three-year agreement follows the previous five-year deal signed in 2016 and will involve using AI to analyse and examine genomics data to better establish the natural possibility people have for a certain disease. Together the Broad Institute and the Massachusetts-based IBM division aim to improve and grow genetic risk scoring by utilising population and hospital-based biobank information, genomic data and electronic health records. Ultimately the initiative intends to make knowledge gained, along with accompanying tools, available to researchers.